We applaud the Biden administration’s delay of a harmful policy.
AMCP CEO Susan Cantrell issues statement in support of PCMA's lawsuit against the Trump administration's attempts to implement a rebate rule that could destabilize Medicare Part D.
Last week, more than 30 experts representing payers, pharmacists, integrated delivery systems, health economists and analysts, patient advocates, academicians, pharmaceutical manufacturers, and other key decision-makers in the managed care setting convened virtually for AMCP’s Partnership Forum “Biosimilars: Policy, Practice, and Post-Marketing Surveillance to Support Treatment and Coverage Decisions” to identify key actions that support the use and development of biosimilars in the U.S. health care system.
The leaders of 18 pharmacy organizations today issued the following statement following the Food and Drug Administration’s approval of the first Emergency Use Authorization for the COVID-19 vaccine.
Following the U.S. Supreme Court decision in the case of Rutledge v. PCMA, AMCP released the below statement.
AMCP Foundation recognizes two student pharmacists from the University of Southern California and University of Washington for the successful completion of the Specialized Summer Internship Program in Health Outcomes, sponsored by AbbVie, Inc.
AMCP Foundation proudly recognizes two student pharmacists who recently completed the Managed Care: Oncology Summer Internship program with the generous support of Pfizer, Inc.’s US Oncology Organized Customer Team.
AMCP Foundation congratulates three student pharmacists who recently completed two innovative programs on managed care pharmacy and nonprofit leadership, through the generous support of Pfizer, Inc.
AMCP Foundation recognizes Montrell Taylor, 2021 PharmD Candidate at Howard University College of Pharmacy, for his successful completion of the Genentech Evidence for Access Summer Internship Program.
Today, the Administration released a final rule, Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals, along with an interim final rule, Most Favored Nations (MFN) Model. In response, AMCP CEO Susan A. Cantrell, RPh, CAE, released the following statement.
Prior to U.S. Supreme Court oral arguments this morning in the case of California vs. Texas, AMCP released the following statement.
AMCP Foundation hosted its most recent Best Poster Competition at AMCP Nexus 2020 Virtual on Wednesday, Oct. 21.